1.
Clin Infect Dis
; 75(2): 330-333, 2022 08 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34996098
RESUMO
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-ß-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.